Suppr超能文献

肾移植后新发糖尿病

New-Onset Diabetes after Kidney Transplantation.

作者信息

Ponticelli Claudio, Favi Evaldo, Ferraresso Mariano

机构信息

Nephrology, Dialysis and Transplantation, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy.

Renal Transplantation, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy.

出版信息

Medicina (Kaunas). 2021 Mar 8;57(3):250. doi: 10.3390/medicina57030250.

Abstract

New-onset diabetes mellitus after transplantation (NODAT) is a frequent complication in kidney allograft recipients. It may be caused by modifiable and non-modifiable factors. The non-modifiable factors are the same that may lead to the development of type 2 diabetes in the general population, whilst the modifiable factors include peri-operative stress, hepatitis C or cytomegalovirus infection, vitamin D deficiency, hypomagnesemia, and immunosuppressive medications such as glucocorticoids, calcineurin inhibitors (tacrolimus more than cyclosporine), and mTOR inhibitors. The most worrying complication of NODAT are major adverse cardiovascular events which represent a leading cause of morbidity and mortality in transplanted patients. However, NODAT may also result in progressive diabetic kidney disease and is frequently associated with microvascular complications, eventually determining blindness or amputation. Preventive measures for NODAT include a careful assessment of glucose tolerance before transplantation, loss of over-weight, lifestyle modification, reduced caloric intake, and physical exercise. Concomitant measures include aggressive control of systemic blood pressure and lipids levels to reduce the risk of cardiovascular events. Hypomagnesemia and low levels of vitamin D should be corrected. Immunosuppressive strategies limiting the use of diabetogenic drugs are encouraged. Many hypoglycemic drugs are available and may be used in combination with metformin in difficult cases. In patients requiring insulin treatment, the dose and type of insulin should be decided on an individual basis as insulin requirements depend on the patient's diet, amount of exercise, and renal function.

摘要

移植后新发糖尿病(NODAT)是肾移植受者常见的并发症。它可能由可改变和不可改变的因素引起。不可改变的因素与一般人群中可能导致2型糖尿病发生的因素相同,而可改变的因素包括围手术期应激、丙型肝炎或巨细胞病毒感染、维生素D缺乏、低镁血症以及免疫抑制药物,如糖皮质激素、钙调神经磷酸酶抑制剂(他克莫司比环孢素更常见)和mTOR抑制剂。NODAT最令人担忧的并发症是主要不良心血管事件,这是移植患者发病和死亡的主要原因。然而,NODAT也可能导致进行性糖尿病肾病,并常与微血管并发症相关,最终导致失明或截肢。NODAT的预防措施包括移植前仔细评估葡萄糖耐量、减轻超重、改变生活方式、减少热量摄入和进行体育锻炼。相应措施包括积极控制全身血压和血脂水平以降低心血管事件风险。应纠正低镁血症和维生素D水平低的情况。鼓励采用限制使用致糖尿病药物的免疫抑制策略。有许多降糖药物可供使用,在困难病例中可与二甲双胍联合使用。在需要胰岛素治疗的患者中,胰岛素的剂量和类型应根据个体情况决定,因为胰岛素需求量取决于患者的饮食、运动量和肾功能。

相似文献

1
New-Onset Diabetes after Kidney Transplantation.肾移植后新发糖尿病
Medicina (Kaunas). 2021 Mar 8;57(3):250. doi: 10.3390/medicina57030250.

引用本文的文献

3
Kidney Transplant: More than Immunological Problems.肾移植:不止是免疫问题。
J Clin Med. 2025 Mar 19;14(6):2101. doi: 10.3390/jcm14062101.
9
New-Onset Diabetes Mellitus after Kidney Transplantation.肾移植后新发糖尿病
J Clin Med. 2024 Mar 27;13(7):1928. doi: 10.3390/jcm13071928.

本文引用的文献

2
2. Classification and Diagnosis of Diabetes: .2. 糖尿病的分类和诊断: 。
Diabetes Care. 2020 Jan;43(Suppl 1):S14-S31. doi: 10.2337/dc20-S002.
9
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.卡格列净与 2 型糖尿病和肾病患者的肾脏结局。
N Engl J Med. 2019 Jun 13;380(24):2295-2306. doi: 10.1056/NEJMoa1811744. Epub 2019 Apr 14.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验